Saturday 31 October 2026 Export PFE’s income statement to Excel — free account

Pfizer Inc.

PFE Healthcare Drug Manufacturers General

Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024. In the quarter to June 2026, revenue grew 2.60%, EPS fell 107.8%, free cash flow grew 125.2% and total debt rose 2.26%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years; insiders bought in the last twelve months.

30.50 0.55 +1.84%

Follow PFE

Alert me

Market cap: $170.7B
P/E: 40.1×
Fwd P/E: 18.6×
Dividend yield: 7.05%
F-score: 6/9
Altman Z: 2.03
Beneish M: −2.52
Dividend safety: 28/100

Overview Business Profile Earnings & Analysis Segments Filings

Pfizer Inc. (PFE) revenue by segment, product and region

Where the money comes from and where it goes

Fiscal 2025: revenue by segment, and margins
Biopharma	61,199	97.79%
Other, not broken out	1,380	2.21%
Gross margin		74.33%
Operating margin		22.76%
Pre-tax margin		12.02%

Revenue by product or service $m

Line	FY2013	FY2012	FY2011	FY2009
Biopharmaceutical	47,878 92.82%	51,214 93.70%	57,747 94.61%	45,448 92.24%
Other, not broken out	3,706 7.18%	3,443 6.30%	3,288 5.39%	3,821 7.76%
Revenue	51,584	54,657	61,035	49,269

Revenue by segment $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2013	FY2012	FY2011	FY2010	FY2009
Biopharma	61,199 97.79%	62,400 98.07%	58,237 97.79%	99,826 108.75%	79,557 108.04%	40,724 97.77%	38,013 92.93%	37,558 92.00%	35,530 67.62%	—	—	—	—	—	—
Upjohn	—	—	—	—	—	—	—	12,484 30.58%	13,447 25.59%	—	—	—	—	—	—
Innovative Health	—	—	—	—	—	—	—	—	—	29,197 55.27%	—	—	—	—	—
Essential Health	—	—	—	—	—	—	—	—	—	23,627 44.73%	—	—	—	—	—
Established Products And Emerging Markets	—	—	—	—	—	—	—	—	—	—	19,672 38.14%	20,195 36.95%	18,509 30.33%	18,760 28.79%	13,947 28.31%
Specialty Care And Oncology	—	—	—	—	—	—	—	—	—	—	14,934 28.95%	15,461 28.29%	16,568 27.15%	16,435 25.22%	8,925 18.11%
Primary Care	—	—	—	—	—	—	—	—	—	—	13,272 25.73%	15,558 28.46%	22,670 37.14%	23,328 35.80%	22,576 45.82%
Other operating segment and other business activities	—	—	—	—	—	—	—	—	—	—	3,574 6.93%	3,443 6.30%	3,288 5.39%	319 0.49%	—
Certain Significant Items	—	—	—	—	—	—	—	—	—	—	132 0.26%	0 0.00%	0 0.00%	0 0.00%	—
Acquisition-related Costs	—	—	—	—	—	—	—	—	—	—	0 0.00%	0 0.00%	0 0.00%	0 0.00%	—
Corporate	—	—	—	—	—	—	—	—	—	—	0 0.00%	0 0.00%	0 0.00%	0 0.00%	—
Other Unallocated	—	—	—	—	—	—	—	—	—	—	0 0.00%	0 0.00%	0 0.00%	0 0.00%	—
Purchase Accounting Adjustments	—	—	—	—	—	—	—	—	—	—	0 0.00%	0 0.00%	0 0.00%	0 0.00%	—
Other operating segments	—	—	—	—	—	—	—	—	—	—	—	—	—	6,323 9.70%	—
Animal Health And Consumer Healthcare	—	—	—	—	—	—	—	—	—	—	—	—	—	—	3,258 6.61%
Nutrition And Other Business Activities	—	—	—	—	—	—	—	—	—	—	—	—	—	—	563 1.14%
Other, not broken out	1,380 2.21%	1,227 1.93%	1,316 2.21%	—	—	927 2.23%	2,892 7.07%	—	3,569 6.79%	—	—	—	—	—	—
Eliminations	—	—	—	(8,033) (8.75%)	(5,921) (8.04%)	—	—	(9,217) (22.58%)	—	—	—	—	—	—	—
Innovative Health and Essential Health	—	—	—	—	—	—	—	—	—	52,824	—	—	—	—	—
Operating Segments	—	—	—	—	—	—	—	—	—	—	47,878	51,214	57,747	58,523	48,706
Revenue	62,579	63,627	59,553	91,793	73,636	41,651	40,905	40,825	52,546	52,824	51,584	54,657	61,035	65,165	49,269

Gross profit by segment $m, and margin

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2013	FY2012	FY2011	FY2010	FY2009
Biopharma	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Gross profit	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

Revenue by region $m

Line	FY2025	FY2024	FY2023	FY2020	FY2019	FY2018	FY2017	FY2016	FY2013	FY2012	FY2011	FY2010	FY2009
U.S.	37,078 59.25%	38,691 60.81%	28,145 47.26%	21,455 51.51%	20,326 49.69%	20,119 49.28%	26,026 49.53%	26,369 49.92%	20,274 39.30%	21,313 38.99%	25,277 41.41%	28,855 44.28%	21,540 43.72%
International Developed Markets	16,188 25.87%	16,057 25.24%	20,910 35.11%	—	—	—	—	—	—	—	—	—	—
International Emerging Markets	9,313 14.88%	8,879 13.95%	10,498 17.63%	—	—	—	—	—	—	—	—	—	—
Emerging Markets	—	—	—	8,372 20.10%	8,828 21.58%	8,618 21.11%	11,399 21.69%	10,420 19.73%	11,225 21.76%	10,843 19.84%	10,115 16.57%	10,263 15.75%	7,046 14.30%
Developed Europe	—	—	—	7,788 18.70%	7,729 18.90%	7,997 19.59%	8,508 16.19%	9,306 17.62%	11,739 22.76%	12,545 22.95%	15,221 24.94%	16,156 24.79%	12,586 25.55%
Developed Rest Of World	—	—	—	4,036 9.69%	4,022 9.83%	4,090 10.02%	6,612 12.58%	6,729 12.74%	8,346 16.18%	9,956 18.22%	10,422 17.08%	9,891 15.18%	8,097 16.43%
Revenue	62,579	63,627	59,553	41,651	40,905	40,825	52,546	52,824	51,584	54,657	61,035	65,165	49,269

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.